Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI311 in Active Thyroid Eye Disease
CTR20223393Phase 3Completed
- Sponsor
- Innovent Biologics
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of sycume in Graves Orbitopathy (GO), sponsored by Innovent Biologics. Started Dec 2022; status: completed.
02
Drugs
sycume
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on CTR20223393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223393.